Lyell Immunopharma, Inc. (LYEL)
$1.46
Rating:
Recommendation:
-
| Symbol | LYEL |
|---|---|
| Price | $1.46 |
| Beta | -1.385 |
| Volume Avg. | 0.72M |
| Market Cap | 366.499M |
| Shares () | - |
| 52 Week Range | 1.39-8.245 |
| 1y Target Est | - |
| DCF Unlevered | LYEL DCF -> | |
|---|---|---|
| DCF Levered | LYEL LDCF -> | |
| ROE | -33.79% | Strong Sell |
| ROA | -32.10% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 8.17% | Neutral |
| P/E | -1.85 | Sell |
| P/B | 0.50 | Neutral |
Latest LYEL news
About
Download (Excel)Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.